PMID- 31040700
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - Clinical efficacy and survival analysis of apatinib combined with docetaxel in 
      advanced esophageal cancer.
PG  - 2577-2583
LID - 10.2147/OTT.S191736 [doi]
AB  - BACKGROUND AND AIM: Standard chemotherapy has limited clinical efficacy in 
      patients with esophageal cancer and there is a significant and unmet clinical 
      need for effective treatment options for these patients. The aim of this study 
      was to compare the clinical efficacy of the novel, targeted drug apatinib 
      combined with docetaxel, and docetaxel combined with S-1 as second- or 
      further-line treatment for patients with advanced esophageal cancer. METHODS: We 
      enrolled 33 patients with advanced esophageal cancer in chemotherapy group or 
      apatinib combined with chemotherapy group in this retrospective study. Apatinib 
      (500 mg) was taken orally once daily; docetaxel was administered at a dose of 75 
      mg/m(2); and S-1 was optional at a dose of 40-60 mg, based on body surface area. 
      The primary endpoint of this study was progression-free survival (PFS). Secondary 
      endpoints included objective response rate (ORR), disease control rate (DCR), and 
      the incidence and severity of adverse events (AEs). RESULTS: No complete response 
      was observed in the two groups. However, two and five patients achieved partial 
      response in the chemotherapy group and the apatinib combined with chemotherapy 
      group, respectively. The ORR and DCR for the chemotherapy group was 11.1% and 
      33.3%, respectively. In the apatinib combination group, ORR and DCR was 88.9% and 
      93.3%, respectively. Anemia (11.1%) and neutropenia (5.6%) were the most frequent 
      grade III/IV AEs observed in the chemotherapy group. In the apatinib combination 
      group, the most frequent grade III/IV AEs were anemia (13.3%), hypertension 
      (6.7%), and proteinuria (6.7%). Median PFS was significantly longer in the 
      apatinib combination group than in the chemotherapy group (175 days vs 85 days, 
      P=0.01). CONCLUSION: The combination of apatinib and docetaxel has a manageable 
      toxicity profile and may prolong survival. Therefore, this combination may be 
      used as as second- or further-line treatment for patients with advanced 
      esophageal cancer.
FAU - Li, Jing
AU  - Li J
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, People's Republic of China, yanruqin@163.com.
FAU - Jia, Yongxu
AU  - Jia Y
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, People's Republic of China, yanruqin@163.com.
FAU - Gao, Yaping
AU  - Gao Y
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, People's Republic of China, yanruqin@163.com.
FAU - Chang, Zhiwei
AU  - Chang Z
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, People's Republic of China, yanruqin@163.com.
FAU - Han, Huiqiong
AU  - Han H
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, People's Republic of China, yanruqin@163.com.
FAU - Yan, Jie
AU  - Yan J
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, People's Republic of China, yanruqin@163.com.
FAU - Qin, Yanru
AU  - Qin Y
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, People's Republic of China, yanruqin@163.com.
LA  - eng
PT  - Journal Article
DEP - 20190408
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6459155
OTO - NOTNLM
OT  - apatinib
OT  - esophageal carcinoma
OT  - survival analysis
OT  - vascular endothelial growth factor
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2019/05/02 06:00
MHDA- 2019/05/02 06:01
PMCR- 2019/04/08
CRDT- 2019/05/02 06:00
PHST- 2019/05/02 06:00 [entrez]
PHST- 2019/05/02 06:00 [pubmed]
PHST- 2019/05/02 06:01 [medline]
PHST- 2019/04/08 00:00 [pmc-release]
AID - ott-12-2577 [pii]
AID - 10.2147/OTT.S191736 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Apr 8;12:2577-2583. doi: 10.2147/OTT.S191736. eCollection 
      2019.